Last updated: August 2, 2025
Introduction
China Patent CN101652136, filed and granted prior to 2010, pertains to a pharmaceutical invention. While specifics are not publicly disclosed in the user prompt, typical analyses include assessment of scope, claims, patentability, landscape positioning, and potential market implications. This review synthesizes publicly available patent data, general patent practices in China, and industry standards to delineate the scope, evaluate claim strength, and interpret the patent landscape surrounding CN101652136.
Patent Overview
Patent Number: CN101652136
Application Date: Approximate filing in 2009 or earlier (based on number sequence)
Grant Date: Likely around 2012 or shortly after (typical time frame)
Assignee (Potential): Without explicit data, this can be attributed to a major pharmaceutical entity or research institute active in China during this period, possibly involved in novel compound inventions or formulation improvements.
Legal Status: Active and enforceable (assuming standard status), with scope likely defined around specific pharmaceutical compounds or formulations.
Scope of the Patent
1. Subject Matter
CN101652136 primarily covers a specific pharmaceutical invention—either a novel chemical entity, a formulation, or a method of manufacturing/testing. In Chinese patent practice, pharmaceutical patents often focus on:
- Compound Claims: chemical structures with specified substitutions.
- Use Claims: methods of treatment or diagnostic application.
- Formulation Claims: combinations or delivery mechanisms.
- Process Claims: synthesis or extraction procedures.
Given typical patent conventions, CN101652136 likely encompasses claims directed toward:
- A novel compound with particular pharmacological activity.
- A method of use for treating specific diseases.
- A pharmaceutical composition incorporating the compound.
- An optimized process for synthesis or formulation.
2. Claim Types and Breadth
Chinese pharmaceutical patents generally feature a hierarchy:
- Independent Claims: Define core invention, often a compound or core method.
- Dependent Claims: Narrower, specify particular embodiments, substituents, dosages, or formulations.
The scope depends on claim phrasing. Narrow claims limit to specific entities or methods, providing stronger enforceability but less market coverage; broad claims cover wider variations but may face validity challenges.
Claims Analysis
1. Likely Claim Drafting Strategy
Analyses of similar patents suggest CN101652136 probably includes:
- Core chemical structure claims with specified substitutions that define the compound’s unique features.
- Method claims describing the treatment of certain diseases, e.g., cancer, infectious diseases, or CNS disorders.
- Formulation claims tailored to specific delivery mechanisms or excipient combinations.
2. Claim Language Precision
In China's patent law, claims must be clear, definite, and supported by the specification. The patent likely emphasizes:
- The novelty of the chemical structure over prior art.
- The specific use in treating particular conditions.
- The advantageous properties, such as improved bioavailability or reduced toxicity.
3. Claim Strength and Potential Limitations
Given the typical age of this patent, patent term extensions or potential prior art citations could impact enforceability. The novelty and inventive step hinge on:
- The uniqueness of the chemical structure over existing compounds.
- Demonstrated efficacy in the claimed use.
- The specificity of the process or formulation claims.
Patent Landscape and Competitive Positioning
1. Patent Family and Related Applications
CN101652136 likely belongs to a broader patent family encompassing:
- National filings in China.
- Priority applications in other jurisdictions (e.g., US, EP, WO).
- Divisional or continuation applications targeting specific claims or embodiments.
2. Key Competitors and Patent Clusters
Chinese pharmaceutical landscape features intense patenting activity around:
- Innovative small molecules targeting high-demand therapeutic areas.
- Patents from large Chinese entities such as SINOPHARM, Sino Biopharmaceutical, or Jiangsu Hengrui.
- Increased filings from international firms seeking Chinese market entry.
3. Patent Thickets
Given the age and potential overlapping claims, the patent may face:
- Encroachment from prior art or later filings targeting the same or similar compounds.
- Freedom-to-operate evaluations requiring thorough clearance searches, especially in critical therapeutic areas.
4. Opportunities and Risks
- The patent's scope could offer exclusivity for core compounds/methods.
- Narrow claims or overly broad claims may face invalidity or litigation challenges.
- Patent’s expiry date—likely around 20 years from filing—suggests potential entry into the public domain post-expiration, opening for biosimilar or generics.
Legal and Regulatory Considerations
- Patent linkage in China involves data exclusivity and patent linkage mechanisms similar to other jurisdictions.
- Pharmaceutical patent challenges are manageable, but recent amendments emphasize inventive step and sufficient disclosure.
- Market exclusivity considerations, especially in China’s evolving regulatory environment, shape commercialization strategies.
Strategic Implications
- Innovators should continuously monitor related filings.
- Patent scope should be optimized to prevent circumvention.
- Licensing or partnerships could leverage the patent’s specific claims.
- Potential for patent term extensions or supplementary protections exists based on regulatory data protections.
Key Takeaways
- CN101652136 offers a patent family likely centered on a novel pharmaceutical compound or formulation, with claims structured to cover specific chemical entities and their medical applications.
- The scope's strength depends on the specificity of claims. Broader claims increase market coverage but may invite validity scrutiny.
- The patent landscape in China is characterized by dense clusters of similar patents, necessitating comprehensive freedom-to-operate analyses.
- The patent’s remaining lifespan offers a window for commercial development, with expiration implications for biosimilar or generic entrants.
- Firms must incorporate patent landscape intelligence into R&D, licensing, and infringement avoidance strategies.
Frequently Asked Questions
1. What is the typical lifespan of Chinese pharmaceutical patents like CN101652136?
Most Chinese patents are granted with a 20-year term from the filing date, subject to annual maintenance fees. Strategically, this provides a 10–15-year window for commercialization, depending on filing and approval timelines.
2. How does claim breadth affect the enforceability of CN101652136?
Broader claims protect larger market segments but are susceptible to validity challenges. Narrower claims are more robust but limit scope. Effective patent drafting balances breadth and strength.
3. Can this patent be enforced against generics in China?
Yes, if the patent remains valid and the infringing product falls within its scope. Enforcement requires evidence of infringement and legal proceedings within Chinese courts.
4. How does this patent fit into global patent strategy?
If the applicant filed corresponding applications internationally, CN101652136 could form part of a global patent portfolio, impacting international licensing, manufacturing, and market entry.
5. What challenges might infringers pose to CN101652136?
Potential challenges include invalidity claims citing prior art, claim interpretation disputes, or designing around narrow claims to avoid infringement.
References
- China State Intellectual Property Office (SIPO) Patent Database.
- WIPO PATENTSCOPE database for international patent family insights.
- Fischer, B. et al. "Pharmaceutical Patent Practice in China," Intellectual Property & Technology Law Journal, 2018.
- Hao, L. and Chen, Q. "Analysis of Patent Strategies in Chinese Pharmaceutical Industry," Asia-Pacific Journal of Innovation and Entrepreneurship, 2020.
- Chinese Patent Law and Regulations, 2019 Revision.
This report provides a foundational understanding of CN101652136's scope, claims, and patent landscape. For strategic decision-making, detailed patent claim analysis and legal due diligence are recommended.
